Link Pharma Chem returned to profitability in Q1FY26, reporting a net profit of ₹31.83 crore for the quarter ended June 30, 2026, compared to a net loss of ₹40.86 crore in the preceding quarter. The company’s revenue from operations rose 12.2% year-on-year to ₹876.84 crore, up from ₹781.48 crore in the same period last year. This turnaround was supported by a significant improvement in pre-tax profits, which stood at ₹38.87 crore against a loss of ₹49.00 crore in the prior quarter.

The Board of Directors approved the unaudited financial results at a meeting held on August 5, 2026, pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the statutory auditors, CNK & Associates LLP, under Standard on Review Engagements (SRE) 2410. The company operates in a single segment: "Manufacture and Sale of Chemicals."

Financial Performance Highlights

The company’s total income for the quarter reached ₹911.73 crore, driven by both operational revenue and other income. Other income surged to ₹34.89 crore from ₹20.92 crore in Q1FY25, contributing significantly to the bottom line. However, total expenses also increased to ₹872.86 crore from ₹751.43 crore in the corresponding period last year, primarily due to higher cost of materials consumed and changes in inventory levels.

What the Numbers Show

A key driver of the current quarter’s profitability was the composition of other income. Under Ind AS 109, the company values its investments at market prices, with fair value gains accounted for in other income. In Q1FY26, fair value net gains on financial assets designated at FVTPL amounted to ₹18.47 crore, compared to a loss of ₹2.86 crore in the previous quarter. Excluding these fair value adjustments, "adjusted other income" stood at ₹16.42 crore, a sharp increase from ₹1.96 crore in Q1FY25. This indicates that while operational revenues grew steadily, a substantial portion of the quarter’s income boost came from investment revaluations rather than core operating margins alone.

Earnings per share (EPS) improved to ₹0.72 from a negative ₹0.92 in the prior quarter. For the full fiscal year FY25, the company had reported a net profit of ₹7.69 crore on revenues of ₹2,743.15 crore. The current quarter’s results suggest a stronger start to FY26, though investors should note the volatility in other income components linked to market valuations.

Link Pharma Chem has scheduled its 41st Annual General Meeting (AGM) for Thursday, August 20, 2026, to be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting will transact ordinary business, including the adoption of audited financial statements for FY26, and special business such as the ratification of cost auditor remuneration and the appointment of secretarial auditors. Shareholders holding securities as of the record date will be eligible to vote electronically during the designated window, ensuring their voice is heard on key governance matters.

The company has fixed August 13, 2026, as the cut-off date for determining shareholder eligibility. Consequently, the Register of Members and Share Transfer Books will remain closed from August 14 to August 20, 2026, in compliance with Section 91 of the Companies Act, 2013, and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This procedural step ensures that only shareholders holding securities on the record date can participate in the virtual meeting.

E-Voting and Meeting Schedule

Shareholders are required to complete their e-voting between August 17 and August 19, 2026. The remote e-voting window opens on Monday, August 17, at 9:00 a.m. and closes on Wednesday, August 19, at 5:00 p.m. The AGM itself commences at 11:30 a.m. IST on August 20. Participants can join the VC/OAVM session via InstaMeet, with login facilities opening 30 minutes prior to the scheduled start time. MUFG India Private Limited (formerly Link Intime India Private Limited) is providing the e-voting services.

Agenda and Regulatory Compliance

The primary objective of the gathering is to consider and adopt the Audited Financial Statements for the financial year ended March 31, 2026. Additionally, shareholders will vote on the re-appointment of Satish Thakur as a director, who retires by rotation and offers himself for re-election.

Special business items include the ratification of remuneration for Cost Auditors M/s. Y. S. Thakar & Co., appointed to audit cost records for FY27. Their proposed remuneration is ₹45,000 per annum plus applicable taxes and reimbursement of actual out-of-pocket expenses. Furthermore, the meeting seeks approval for the appointment of Vijay Bhatt & Co., Practicing Company Secretaries, as Secretarial Auditors for a four-year term from FY27 to FY30, aligning with Section 204 of the Companies Act, 2013, and Regulation 24A of the SEBI Listing Regulations. The company has appointed Komal Bhojwani, Company Secretary & Compliance Officer, to oversee the compliance aspects of the meeting.

KYC Update Reminder for Physical Holders

In a separate communication dated July 28, 2026, the company reminded shareholders holding physical securities to update their Know Your Customer (KYC) details pursuant to SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024. The circular mandates that security holders must record PAN, Address with PIN code, Mobile Number, Bank Account details, Specimen Signature, and choice of Nomination.

Failure to update these details may impact payment eligibility. As per the circular, security holders whose folios lack updated PAN, nomination, contact details, bank account details, or specimen signatures will only be eligible for payments, including dividends, through electronic mode with effect from April 1, 2024. The company encourages all physical holders to dematerialise their securities and register email IDs to avail online services.